Recursion Pharmaceuticals

RXRX

Market cap $1.91B

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.53 per share a year ago.

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript

Recursion Pharmaceuticals stock up on narrower Q4 loss as revenues jump on Roche milestone, beating estimates and boosting cash runway into 2028.

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and full year ending December 31, 2025.

IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.

Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes' Lightning Talk at the NVIDIA GTC AI Conference & Expo happening March 16-19 in San Jose. Moderated by Stacie Calad-Thomson, Business Development Lead for Healthcare and Life Sciences at NVIDIA, the talk, “AI Agents, Robotics, and Digital Twins: The Full Stack of Self-Driving Labs and Biomanufacturing,” will showcase how AI, automation, and robotics are driving the new era of drug discovery and development.

Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference - Monday, March 2, 2026 Leerink Partners 2026 Global Healthcare Conference - Monday, March 9, 2026 Jefferies 2026 Biotech on the Beach Summit — Wednesday, March 11, 2026 KeyBanc 2026 Healthcare Forum — Tuesday, March 17, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com . About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives.

Cathie Wood's Ark Invest bought shares in Figma, CoreWeave, and Recursion Pharmaceuticals on Friday. Figma stock has fallen 30% this year, but it's been rising in recent days with a strong quarterly report along the way.

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.53, indicating a +2.02% shift from the previous trading day.

Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT